2 weeks Ago By ABMN Staff
Edwards Lifesciences Co. ( NYSE:EW – Get Free Report ) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 11,380,000 shares, an increase of 81.
8% from the August 31st total of 6,260,000 shares. Based on an average daily trading volume, of 6,260,000 shares, the days-to-cover ratio is currently 1.8 days.
Currently, 1.9% of the company’s stock are sold short. Analyst Upgrades and Downgrades Several brokerages have commented on EW.
Barclays decreased their price objective on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th.
The Goldman Sachs Group lowered their price target on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating on the stock in a report on Friday, July 26th.
Piper Sandler reduced their price objective on Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th.
Citigroup upped their target price on Edwards Lifesciences from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th.
Finally, Baird R W cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Sixteen analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.
com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.82. View Our Latest Stock Report on Edwards Lifesciences Edwards Lifesciences Price Performance Edwards Lifesciences ( NYSE:EW – Get Free Report ) last announced its quarterly earnings data on Wednesday, July 24th.
The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.
01. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.
55%. The company had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.
65 billion. During the same quarter last year, the firm posted $0.66 EPS.
The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. As a group, research analysts predict that Edwards Lifesciences will post 2.
71 EPS for the current fiscal year. Insider Buying and Selling In related news, VP Donald E. Bobo, Jr.
sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $66.08, for a total value of $330,400.
00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.
95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.
35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, VP Donald E.
Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, August 14th. The stock was sold at an average price of $66.
08, for a total value of $330,400.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.
88. The disclosure for this sale can be found here . Insiders have sold a total of 16,250 shares of company stock worth $1,218,138 in the last ninety days.
1.29% of the stock is owned by insiders. Institutional Trading of Edwards Lifesciences Several large investors have recently bought and sold shares of the business.
Allspring Global Investments Holdings LLC lifted its stake in Edwards Lifesciences by 4.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock worth $31,603,000 after purchasing an additional 14,087 shares in the last quarter.
Empowered Funds LLC lifted its position in Edwards Lifesciences by 151.2% during the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after buying an additional 12,112 shares in the last quarter.
Cetera Advisors LLC boosted its stake in Edwards Lifesciences by 175.1% during the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock worth $3,640,000 after buying an additional 24,242 shares during the last quarter.
TD Asset Management Inc grew its holdings in Edwards Lifesciences by 95.1% in the 4th quarter. TD Asset Management Inc now owns 1,323,611 shares of the medical research company’s stock valued at $100,925,000 after buying an additional 645,204 shares in the last quarter.
Finally, Sei Investments Co. increased its stake in shares of Edwards Lifesciences by 10.8% in the 4th quarter.
Sei Investments Co. now owns 558,031 shares of the medical research company’s stock worth $42,550,000 after acquiring an additional 54,595 shares during the last quarter. Hedge funds and other institutional investors own 79.
46% of the company’s stock. About Edwards Lifesciences ( Get Free Report ) Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Recommended Stories Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter ..
